Basit öğe kaydını göster

dc.contributor.authorKirnap, Nazli Gulsoy
dc.contributor.authorKirnap, Mahir
dc.contributor.authorSayin, Burak
dc.contributor.authorAkdur, Aydincan
dc.contributor.authorTutuncu, Neslihan Bascil
dc.contributor.authorHaberal, Mehmet
dc.date.accessioned2021-06-30T18:22:34Z
dc.date.available2021-06-30T18:22:34Z
dc.date.issued2020
dc.identifier.issn0041-1345en_US
dc.identifier.urihttp://hdl.handle.net/11727/6241
dc.description.abstractBackground. Kidney transplantation (KT) corrects secondary hyperparathyroidism. However, persistent hyperparathyroidism (pHPT) may be observed in some patients post-KT. This study aims to evaluate the risk factors and treatment options for pHPT. Materials and methods. The study population comprises 1054 patients who underwent KT between January 2001 and May 2019. Serum samples were analyzed for calcium (Ca), phosphorus, creatinine, intact parathyroid hormone (iPTH) and estimated glomerular filtration rate. Results. The prevalence of pHPT following KT is 14%. Ninety pHPT patients were compared with 550 non-pHPT patients. The median duration of pre-KT dialysis was longer, and pre-KT serum Ca, P, and iPTH levels were significantly higher in the pHPT group than the non-HPT group. The pHPT of 46 patients (51%) received medical treatment. The remaining 44 patients (49%) had parathyroidectomy (PTx) if symptoms or signs (or both) of pHPT continued. Subtotal PTx was performed in 35 patients, and minimally invasive PTx was performed in 9 patients. Conclusion. Based on our study results, the most important risk factors for post-KT pHPT are long dialysis duration and high pre-KT iPTH levels. In patients who underwent KT, if pHPT lasts longer than 1 year, surgical treatment is the recommended approach. Based on our experience, the treatment method to be performed in pHPT should be 3+1/2 PTx.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.transproceed.2019.11.020en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSUBTOTAL PARATHYROIDECTOMY INCREASESen_US
dc.subjectGROWTH-FACTOR 23en_US
dc.subjectTERTIARY HYPERPARATHYROIDISMen_US
dc.subjectRENAL-TRANSPLANTATIONen_US
dc.subjectLESS-THANen_US
dc.subjectMINERAL METABOLISMen_US
dc.subjectSURGICAL-TREATMENTen_US
dc.subjectBLOOD-PRESSUREen_US
dc.subjectRECIPIENTSen_US
dc.subjectCOMPLICATIONSen_US
dc.titleRisk Factors and Treatment Options for Persistent Hyperparathyroidism After Kidney Transplantationen_US
dc.typearticleen_US
dc.relation.journalTRANSPLANTATION PROCEEDINGSen_US
dc.identifier.volume52en_US
dc.identifier.issue1en_US
dc.identifier.startpage157en_US
dc.identifier.endpage161en_US
dc.identifier.wos000512320200025en_US
dc.identifier.scopus2-s2.0-85077651581en_US
dc.contributor.pubmedID31924405en_US
dc.contributor.orcID0000-0002-8726-3369en_US
dc.contributor.orcID0000-0002-3462-7632en_US
dc.contributor.orcID0000-0002-1816-3903en_US
dc.contributor.orcID0000-0001-8287-6572en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAA-3068-2021en_US
dc.contributor.researcherIDAAJ-8097-2021en_US
dc.contributor.researcherIDABG-5027-2020en_US
dc.contributor.researcherIDJ-3707-2015en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster